이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Faes Farma 미래 성장

Future 기준 확인 0/6

Faes Farma 의 수익은 연간 1.9% 감소할 것으로 예상되는 반면, 연간 수익은 1.6% 로 증가할 것으로 예상됩니다. 1.6% 연간. EPS는 연간 2% 만큼 쇠퇴할 것으로 예상됩니다. 자기자본이익률은 3년 후 11.3% 로 예상됩니다.

주요 정보

-2.6%

수익 성장률

-2.5%

EPS 성장률

Pharmaceuticals 수익 성장	15.4%
매출 성장률	1.1%
향후 자기자본 수익률	11.1%
애널리스트 커버리지	Low
마지막 업데이트	31 Jul 2024

최근 미래 성장 업데이트

Faes Farma, S.A. (BME:FAE) Just Released Its Full-Year Earnings: Here's What Analysts Think

Mar 01

Faes Farma, S.A. (BME:FAE) Interim Results: Here's What Analysts Are Forecasting For This Year

Jul 31

Recent updates

Faes Farma, S.A. (BME:FAE) Just Released Its Full-Year Earnings: Here's What Analysts Think

Mar 01

Faes Farma, S.A. (BME:FAE) Interim Results: Here's What Analysts Are Forecasting For This Year

Jul 31

Is Faes Farma (BME:FAE) Using Too Much Debt?

May 01

Estimating The Fair Value Of Faes Farma, S.A. (BME:FAE)

Apr 07

Does Faes Farma, S.A. (BME:FAE) Have A Place In Your Dividend Portfolio?

Mar 22

Faes Farma's (BME:FAE) Solid Earnings May Rest On Weak Foundations

Mar 06

Faes Farma (BME:FAE) Has Compensated Shareholders With A Respectable 61% Return On Their Investment

Feb 22

I Ran A Stock Scan For Earnings Growth And Faes Farma (BME:FAE) Passed With Ease

Jan 16

Faes Farma (BME:FAE) Seems To Use Debt Rather Sparingly

Dec 08

수익 및 매출 성장 예측

BME:FAE - 애널리스트의 미래 추정치 및 과거 재무 데이터 (EUR Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	499	89	94	107	3
12/31/2025	490	92	79	110	3
12/31/2024	476	87	33	104	3
6/30/2024	494	97	44	106	N/A
3/31/2024	482	95	N/A	N/A	N/A
12/31/2023	473	92	-1	101	N/A
9/30/2023	472	90	N/A	N/A	N/A
6/30/2023	469	90	-9	98	N/A
3/31/2023	467	91	N/A	N/A	N/A
12/31/2022	462	89	26	107	N/A
9/30/2022	460	86	N/A	N/A	N/A
6/30/2022	466	88	50	113	N/A
3/31/2022	449	88	N/A	N/A	N/A
12/31/2021	429	82	20	80	N/A
9/30/2021	416	81	N/A	N/A	N/A
6/30/2021	398	74	8	56	N/A
3/31/2021	394	73	N/A	N/A	N/A
12/31/2020	411	73	53	78	N/A
9/30/2020	408	77	N/A	N/A	N/A
6/30/2020	407	73	57	78	N/A
3/31/2020	409	68	N/A	N/A	N/A
12/31/2019	383	64	46	68	N/A
9/30/2019	379	60	N/A	N/A	N/A
6/30/2019	363	59	51	74	N/A
3/31/2019	351	54	N/A	N/A	N/A
12/31/2018	340	52	40	59	N/A
9/30/2018	334	51	N/A	N/A	N/A
6/30/2018	330	49	40	58	N/A
3/31/2018	308	47	N/A	N/A	N/A
12/31/2017	282	41	N/A	42	N/A
9/30/2017	266	39	N/A	N/A	N/A
6/30/2017	250	39	N/A	43	N/A
3/31/2017	241	38	N/A	N/A	N/A
12/31/2016	237	37	N/A	50	N/A
9/30/2016	226	35	N/A	N/A	N/A
6/30/2016	222	34	N/A	40	N/A
3/31/2016	220	32	N/A	N/A	N/A
12/31/2015	214	30	N/A	41	N/A
9/30/2015	207	28	N/A	N/A	N/A
6/30/2015	203	27	N/A	42	N/A
3/31/2015	196	26	N/A	N/A	N/A
12/31/2014	198	25	N/A	32	N/A
9/30/2014	195	23	N/A	N/A	N/A
6/30/2014	194	24	N/A	20	N/A
3/31/2014	192	20	N/A	N/A	N/A
12/31/2013	193	23	N/A	32	N/A
9/30/2013	196	21	N/A	N/A	N/A

애널리스트 미래 성장 예측

수입 대 저축률: FAE 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -1.9% ).

수익 vs 시장: FAE 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -1.9% ).

고성장 수익: FAE 의 수익은 향후 3년간 감소할 것으로 예상됩니다.

수익 대 시장: FAE 의 수익(연간 1.6% ) Spanish 시장( 4.7% 보다 느리게 성장할 것으로 예상됩니다. 4.7% 연간).

고성장 수익: FAE 의 수익(연간 1.6% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: FAE 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 11.3 %).

Faes Farma 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Faes Farma, S.A. (BME:FAE) Just Released Its Full-Year Earnings: Here's What Analysts Think

Faes Farma, S.A. (BME:FAE) Interim Results: Here's What Analysts Are Forecasting For This Year

Recent updates

Second quarter 2024 earnings released

Now 21% overvalued after recent price rise

Faes Farma, S.A. (BME:FAE) Just Released Its Full-Year Earnings: Here's What Analysts Think

Full year 2023 earnings released

Faes Farma, S.A. to Report Fiscal Year 2023 Results on Feb 27, 2024

Faes Farma, S.A. to Report Fiscal Year 2023 Results on Feb 27, 2024

Now 21% undervalued

New major risk - Revenue and earnings growth

Faes Farma (BME:FAE) Is Due To Pay A Dividend Of €0.0316

Faes Farma (BME:FAE) Will Pay A Dividend Of €0.0316

Does Faes Farma (BME:FAE) Have A Healthy Balance Sheet?

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

Second quarter 2023 earnings released

Faes Farma, S.A. (BME:FAE) completed the acquisition of NovoSci.

First quarter 2023 earnings released

Here's Why Faes Farma (BME:FAE) Can Manage Its Debt Responsibly

Now 20% undervalued after recent price drop

Upcoming dividend of €0.03 per share

Less than half of directors are independent

Third quarter 2022 earnings released

Is There An Opportunity With Faes Farma, S.A.'s (BME:FAE) 50% Undervaluation?

Is Faes Farma (BME:FAE) A Risky Investment?

Second quarter 2022 earnings released

Faes Farma (BME:FAE) Ticks All The Boxes When It Comes To Earnings Growth

Less than half of directors are independent

Is Faes Farma (BME:FAE) Using Too Much Debt?

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Faes Farma (BME:FAE) Is Increasing Its Dividend To €0.14

Upcoming dividend of €0.14 per share

Faes Farma's (BME:FAE) Dividend Will Be Increased To €0.17

Is Faes Farma (BME:FAE) A Risky Investment?

Faes Farma, S.A. (BME:FAE) Interim Results: Here's What Analysts Are Forecasting For This Year

Second quarter 2021 earnings released

First quarter 2021 earnings released

Is Faes Farma (BME:FAE) Using Too Much Debt?

Estimating The Fair Value Of Faes Farma, S.A. (BME:FAE)

Does Faes Farma, S.A. (BME:FAE) Have A Place In Your Dividend Portfolio?

Faes Farma, S.A. (BME:FAE) completed the acquisition of Gobal Farma.

Faes Farma's (BME:FAE) Solid Earnings May Rest On Weak Foundations

Faes Farma (BME:FAE) Has Compensated Shareholders With A Respectable 61% Return On Their Investment

New 90-day high: €3.96

I Ran A Stock Scan For Earnings Growth And Faes Farma (BME:FAE) Passed With Ease

Faes Farma (BME:FAE) Seems To Use Debt Rather Sparingly

New 90-day high: €3.90

New 90-day high: €3.74

New 90-day low: €3.20

New 90-day low - €3.37

New 90-day low - €3.40

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견